Register for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
RocheSwiss diversified pharma. Carmot acquisition (December 2023, $2.7B) brought CT-388 (about 23% placebo-adjusted weight loss at 48 weeks Phase 2), CT-996 oral, and CT-868. Zealand licensing deal ($1.65B) added petrelinitide amylin program.
Carmot acquisition (December 2023, $2.7B) brought CT-388 (Phase 2 showed about 23% placebo-adjusted weight loss at 48 weeks), CT-996 oral, and CT-868. Zealand licensing deal ($1.65B, 2024) added petrelinitide amylin program. CT-388 entering Phase 3 in 2026.